ImmuCell (ICCC) to Release Quarterly Earnings on Monday

ImmuCell (NASDAQ:ICCC) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, May 13th.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings results on Wednesday, February 13th. The biotechnology company reported ($0.19) earnings per share for the quarter. The firm had revenue of $2.94 million for the quarter. ImmuCell had a negative return on equity of 7.75% and a negative net margin of 21.13%.

NASDAQ:ICCC remained flat at $$6.40 on Thursday. 27 shares of the company traded hands, compared to its average volume of 8,479. The company has a quick ratio of 1.59, a current ratio of 2.50 and a debt-to-equity ratio of 0.39. ImmuCell has a fifty-two week low of $5.55 and a fifty-two week high of $9.30.

TRADEMARK VIOLATION NOTICE: “ImmuCell (ICCC) to Release Quarterly Earnings on Monday” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2019/05/09/immucell-iccc-to-release-quarterly-earnings-on-monday.html.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E.

Read More: Outstanding Shares, Buying and Selling Stocks

Earnings History for ImmuCell (NASDAQ:ICCC)

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply